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Abstract
Background—MYCN oncogene amplification has been defined as the most important prognostic
factor for neuroblastoma, the most common solid extracranial neoplasm in children. High copy
numbers are strongly associated with rapid tumor progression and poor outcome, independently of
tumor stage or patient age, and this has become an important factor in treatment stratification.
Procedure—By Real Time Quantitative PCR analysis, we evaluated the clinical relevance of
circulating MYCN DNA of 267 patients with locoregional or metastatic neuroblastoma in children
less than 18 months of age.
Results—For patients in this age group with INSS stage 4 or 4S NB and stage 3 patients, serum-
based determination of MYCN DNA sequences had good sensitivity (85%, 83% and 75%
respectively) and high specificity (100%) when compared to direct tumor gene determination. In
contrast, the approach showed low sensitivity patients with stage 1 and 2 disease.
Conclusion—Our results show that the sensitivity of the serum-based MYCN DNA sequence
determination depends on the stage of the disease. However, this simple, reproducible assay may
represent a reasonably sensitive and very specific tool to assess tumor MYCN status in cases with
stage 3 and metastatic disease for whom a wait and see strategy is often recommended.
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Introduction
The potential application of circulating DNA in the diagnosis and prognosis of cancer was
first demonstrated in 1977, when high levels of circulating DNA were detected in the serum
of cancer patients, and the levels of circulating DNA decreased when the patients responded
to radiotherapy [1]. Subsequently, a large number of tumour-associated genetic and
epigenetic changes were detected in the plasma/serum of cancer patients, including Ras and
p53 mutations, microsatellite alterations, aberrant promoter hypermethylation of several
genes, rearranged immunoglobulin heavy chain DNA, mitochondrial DNA mutations, and
tumour-related viral DNA [2–4]. Recently, we and others demonstrated that high levels of
circulating MYCN DNA sequences, as assessed by real-time quantitative PCR, were present
in the peripheral blood of patients with MYCN-amplified (MNA) neuroblastoma [5–7]. As
the assessment of MYCN status is paramount to prognosis determination and therapeutic
stratification in patients with neuroblastoma (NB) [8], this observation suggested that levels
of circulating MYCN DNA sequences could serve as a sensitive, yet non-invasive,
prognostic marker at the time of diagnosis. Based on these preliminary data, we have now
determined the clinical relevance of circulating MYCN DNA by analyzing blindly serum
samples from a large cohort of patients less than 18 months of age with neuroblastoma and
locoregional or metastatic disease.
Patients and methods
Patients
Patients diagnosed with NB were enrolled in the study with informed consent of their
parents. This study was conducted under research protocols approved by each institutional
review board. Two hundred and sixty-seven serum samples (Stages 1 and 2, n=34; stage 3,
n=43; stage 4, n=124; stage 4S, n= 66) were obtained from the Children’s Oncology Group
and from the tumor repositories of different European countries (for INSS stage 3 NB
patients) at diagnosis. This retrospective study was blinded in that the sera were analyzed
without knowledge of the tumor MYCN status determined at the time of diagnosis using
standard methodology.
DNA isolation
Circulating DNA was extracted from 200 µl of frozen serum samples using the QIAmp
DNA blood kit (Qiagen, Courtaboeuf, France) according to the "blood and body fluid
protocol" recommended by the manufacturer.
Real-Time Quantitative PCR
Circulating MYCN DNA was analyzed by quantitative real-time PCR, as previously
described [7]. Briefly, TaqMan PCR was performed using the ABI Prism 7000 Sequence
Detection System (Applied Biosystems, Foster City, CA). Amplification mixtures (25 µl)
consisted of template DNA (5 µl), 1× TaqMan Universal PCR MasterMix (Applied
Biosystems), 200 nmol/L of each primer, and 100 nmol/L of fluorogenic probe.
Simultaneously to the MYCN sequence, NAGK, located at 2p12, was measured and used as a
single-copy gene reference. All PCR reactions were performed with one cycle of 95°C for
10 minutes, followed by PCR amplification with 40 cycles of 95°C for 15 seconds and 60°C
for 1 minute. Standard curves were constructed in each PCR run with four-fold serial
dilutions containing 100, 10, 1 and 0.1 ng/µL of a healthy donor's DNA. The dosages of the
target genes in each sample were interpolated from these standard curves. The MYCN copy
number in a given DNA sample was determined by the ratio of MYCN dosage to NAGK
dosage (M/N ratio). A MYCN/NAGK cut-off ratio of 5 was considered indicative of a high
Combaret et al. Page 2
Pediatr Blood Cancer. Author manuscript; available in PMC 2010 September 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
level of circulating MYCN DNA sequences and a surrogate for tumoral MYCN amplification.
The MYCN copy numbers were expressed as the average of two measurements.
Results
Determination of the number of MYCN copies in the peripheral blood would facilitate the
prediction of prognosis in patients with neuroblastoma. To assess whether this serum assay
may supplant biopsy for evaluating this key biomarker, our cohort was enriched for patients
in which tumor biopsy may be difficult (such as symptomatic infants with stage 4S disease)
or deferred by clinical discretion (such as children with observable localized masses). Of the
124 patients with INSS stage 4 NB enrolled in the study, 83 had non-MNA tumors and 41
had MNA tumors. A high level of circulating MYCN DNA sequences was found in 35 of the
41 cases with MNA tumors. Of the 66 patients with INSS stage 4S disease, 6 had MNA
tumors, and a high level of circulating MYCN DNA was found in 5 of these 6 cases. Thus, in
patients less than 18 months of age with INSS stage 4 or 4S NB, serum-based determination
of MYCN DNA sequences had good sensitivity (85% and 83%, respectively) and perfect
specificity (100%, no false positives observed in either group) when compared to direct
tumor MYCN gene determination (Table I).
Thirty-four serum samples were obtained at diagnosis from patients with INSS stages 1 and
2, and 43 from patients with INSS stage 3 disease (i.e., patients with locoregional NB).
Overall, no false positive cases were observed. Twelve of the 16 INSS patients with Stage 3
disease and MNA tumors showed high levels of circulating MYCN DNA sequences (75%
sensitivity). In contrast, significant levels of circulating MYCN DNA sequences were
detected in the serum of only 1 of the 10 INSS stage 1–2 patients with MNA tumors,
demonstrating low sensitivity of the method in this cohort (Table I).
Discussion
Our results show that the sensitivity of serum-based MYCN DNA sequence determination
depends on the stage of NB. Whereas most patients with metastatic NB show high levels of
circulating MYCN DNA sequences, the sensitivity of the assay appears to be lower for
patients with localized NB, in particular those with a low tumor burden (INSS stages 1 and
2). This observation could be explained by the smaller quantity of dying tumor cells
releasing tumor DNA in patients with favorable locoregional NB, whereas biologically
aggressive disease is more frequently associated with areas of necrosis resulting in higher
DNA release. However, other possibilities include a spontaneous and active release of DNA
by proliferating cancer cells as observed withlymphocytes [9,10] or a stability of circulating
tumoral DNA explained by a low activity of DNase I and of DNase II in patients with
malignant diseases compared with the activity observed in healthy people [11]. Some of the
rare false negative cases reported in patients with MNA tumors could be due to
heterogeneous tumors with low MYCN amplification. Two patients with tumor MYCN
amplification could only be identified using FISH analysis whereas MYCN detection using
Real Time quantitative PCR remained negative. Beyond these particular cases, it appears
that the accuracy of the assay is directly dependent on the quality of the serum samples. In
the present retrospective study, false negative cases could reflect variations in the method
used for serum collection and handling. We identified no false positive results using this
serum assay as a surrogate for tumor MYCN amplification; the implementation of this assay
is therefore unlikely to cause over treatment in patients erroneously scored as having MYCN
amplified tumors.
In conclusion, the detection of MYCN sequences in sera appears to be a specific tool for the
determination of tumor MYCN amplification in patients with neuroblastoma. The possibility
Combaret et al. Page 3
Pediatr Blood Cancer. Author manuscript; available in PMC 2010 September 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
of determining the MYCN status of patients with neuroblastoma from a blood sample could
potentially eliminate cases with unknown MYCN status (26% of all neuroblastoma patients,
according to a study by Matthay et al. [12]) so that these patients can receive more
appropriate treatment. Furthermore, this simple, reproducible assay may represent a safe,
reasonably sensitive and very specific tool to assess tumor MYCN status in the cases with
stage 3 and metastatic disease for whom a wait and see strategy is often recommended.
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Table I
Detection of high levels of MYCN DNA sequences in the peripheral blood and correlation with patient
clinical status.
Non Amplified
Tumor
Amplified
Tumor
MYCN (stages 1 and 2) n=34 24 10
- No detection of circulating MYCN DNA sequences 24 9
- Detection of circulating MYCN DNA sequences 0 1
MYCN (stage 3) n=43 27 16
- No detection of circulating MYCN DNA sequences 27 4
- Detection of circulating MYCN DNA sequences 0 12
MYCN (stage 4 < 18 months) n =124 83 41
- No detection of circulating MYCN DNA sequences 83 6
- Detection of circulating MYCN DNA sequences 0 35
MYCN (stage 4 S) n =66 60 6
- No detection of circulating MYCN DNA sequences 60 1
- Detection of circulating MYCN DNA sequences 0 5
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